Organic growth in revenues and adjusted EBITDA reconcile to reported growth as follows:
Adjusted
Revenue EBITDA
-------------------------------------------------------------------------
Reported growth 92% 140%
Growth attributable to the acquisition of MD (83%) (100%)
Impact of currency fluctuations on growth 1% 33%
-------------------------------------------------------------------------
Organic growth 10% 73%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
MD has been a strong contributor to segment revenues and adjusted EBITDA since we acquired it. Given the strong start, we believe the division is on track to meet or exceed the expected $190 million in revenues and $45 - $50 million in adjusted EBITDA in the first full year of ownership. MD revenues were up 16% compared to the same three-month period in their fiscal 2006.
MDS acquired Molecular Devices effective March 20, 2007. During the
third quarter we conti
'/>"/>
| SOURCE MDS Inc. Copyright©2007 PR Newswire. All rights reserved |